Panbela Therapeutics shares are trading higher after the company divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds for $9.5 million.
Portfolio Pulse from Benzinga Newsdesk
Panbela Therapeutics has sold certain assets in its Eflornithine Pediatric Neuroblastoma Program to US WorldMeds for $9.5 million, causing its shares to trade higher.
July 19, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Panbela Therapeutics' stock is trading higher following the divestment of certain assets for $9.5 million.
The sale of assets is a positive financial move for Panbela Therapeutics, providing the company with additional capital. This has led to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100